Antibodies News and Research

RSS

Research proves effectiveness of vaccine against leishmaniasis

The disease is considered endemic in the south states of Mexico. A research executed in the Autonomous University of Yucatan (UADY) has successfully proved, in test animals, the effectiveness of a vaccine that immunizes the organism against leishmaniasis, an ailment transmitted through insects very similar to mosquitos and mainly presents symptoms in the skin, liver or spleen.

3 Dec 2013

Tel Aviv University researchers discover a protein that kills bacteria

In the arms race between bacteria and modern medicine, bacteria have gained an edge. In recent decades, bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat. Scientists worry that a particularly virulent and deadly "superbug" could one day join the ranks of existing untreatable bacteria, causing a public health catastrophe comparable with the Black Death.

3 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra, Inc., a developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds from an upsized and final closing of its Series A financing round. The company also announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, which follows the recent appointment of Brian Pereira, M.D. as President and Chief Executive Officer of Visterra this past summer.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

UK to fund over 70 new Centres for Doctoral Training

Details of how a -350 million fund will be used to train over 3,500 postgraduate students in engineering and physical sciences, will be announced today by Universities and Science Minister, David Willetts.

28 Nov 2013

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so far.

27 Nov 2013

European research project examines toxicity factor to fight AIDS

December 1st is the annual World AIDS Day, a perfect opportunity to look at how medical research is progressing to fight the disease.

27 Nov 2013

Researchers show how unusual properties of A3G protein help fight HIV infection

A collaborative team led by a Northeastern University professor may have altered the way we look at drug development for HIV by uncovering some unusual properties of a human protein called APOBEC3G.

27 Nov 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.

21 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

BBI Solutions, a world leader in immunoassay development and contract manufacturing, recently launched its unique range of Recombinant Fab Monoclonal Antibodies at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas.

19 Nov 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Australian scientists have described an exquisitely balanced interplay of four molecules that trigger and govern antibody production in immune cells. As well as being an important basic science discovery, it helps explain why people with mutations in any one of the associated genes cannot fight infection effectively, and develop rare and crippling immunodeficiency disorders.

18 Nov 2013

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Antibodies News and Research

Research proves effectiveness of vaccine against leishmaniasis

Tel Aviv University researchers discover a protein that kills bacteria

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

Study brings effective hepatitis C cure closer to reality

UK to fund over 70 new Centres for Doctoral Training

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

European research project examines toxicity factor to fight AIDS

Researchers show how unusual properties of A3G protein help fight HIV infection

EU-funded project develops new type of vaccine to tackle HIV virus infection

SillaJen executes definitive merger agreement to acquire Jennerex

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Covagen, TRL expand research collaboration to generate bispecific FynomAb

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo